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 Genotype 1 of the hepatitis C virus (HCV) is the most prevalent of the variants 
of this virus. Its two main subtypes, HCV-1a and HCV-1b, are associated to differences 
in epidemic features and risk groups, despite sharing similar features in most biological 
properties. We have analyzed the impact of positive selection on the evolution of 
these variants using complete genome coding regions, and compared the levels of 
genetic variability and the distribution of positively selected sites. We have also 
compared the distributions of positively selected and conserved sites considering 
different factors such as RNA secondary structure, the presence of different epitopes 
(antibody, CD4 and CD8), and secondary protein structure. Less than 10% of the 
genome was found to be under positive selection, and purifying selection was the main 
evolutionary process acting in both subtypes. We found differences in the number of 
positively selected sites between subtypes in several genes (Core, HVR2 in E2, P7, 
helicase in NS3 and NS4a). Heterozygosity values in positively selected sites and the 
rate of non-synonymous substitutions were significantly higher in subtype HCV-1b. 
Logistic regression analyses revealed that similar selective forces act at the genome 
level in both subtypes: RNA secondary structure and CD4 T-cell epitopes are associated 
with conserved sites, while CD8 T-cell epitopes are associated with positive selection in 
both subtypes. These results indicate that similar selective constraints are acting along 
HCV-1a and HCV-1 b genomes, despite some differences in the distribution of 
positively selected sites at independent genes. 




 Hepatitis C Virus (HCV) is the main causal agent of non-A non-B viral hepatitis, a 
pandemic with a global prevalence of 2.8%, affecting more than 185 million people 
worldwide (Mohd Hanafiah et al. 2013). HCV belongs to the genus Hepacivirus in the 
Flaviviridae family and its single, positive-sense, single-stranded RNA genome of 9.6 kb 
encodes a polyprotein of more than 3000 amino acids (Takamizawa et al. 1991). This 
polyprotein is cleaved into 3 structural (Core, Envelope 1(E1), E2) and 7 non-structural 
(P7, NS2, NS3, NS4A, NS4b, NS5A and NS5b) proteins by means of both viral and 
human proteases (reviewed in Lindenbach and Rice 2005).  
Like most RNA viruses, HCV is highly variable genetically and is phylogenetically 
divided into seven genotypes (named from 1 to 7) (Smith et al. 2014) which present 
more than 30% divergence at the nucleotide level among them. Most genotypes are 
further divided into subtypes, with 20-25% divergence among them (Simmonds et al. 
1993). Genotype 1 is the most prevalent variant (Messina et al. 2015) and also the one 
with the lowest sustained viral response (SVR) rate to treatment with pegylated 
interferon and ribavirin (Pang et al. 2009), which still remains as the most frequent 
treatment for hepatitis C infection. More than 10 HCV-1 subtypes have been reported 
so far (Kuiken et al. 2005). Among them, subtypes 1a and 1b are the most prevalent 
and cause about 40% of the total infections by the virus. 
 These two viral variants present some differences. There are epidemiological 
differences between their major transmission groups and these influence their 
phylodynamics. HCV-1a has been historically associated with transmission among 
intravenous drug users and HCV-1b with transfusions and other nosocomial and 
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community transmissions (Shepard et al. 2005). Although subtype 1b apparently 
appeared around 10 years later than subtype 1a, it started an explosive growth phase 
20 years earlier (in the 1940s), coincident with the start of widespread use of blood 
and blood derivatives in transfusions (Magiorkinis et al. 2009). Clinical differences 
between these two subtypes may also exist: sustained viral response (SVR) to 
treatment with pegylated interferon and ribavirin has been reported to be significantly 
higher in subtype 1a than in 1b (Pellicelli et al. 2012). Finally, at the genetic level, 
Torres-Puente et al. (2008) reported differences in genetic variability between these 
two subtypes, with HCV-1b showing higher nucleotide diversity in genes E1, E2 and 
NS5A.  
Most published studies detecting positively selected sites in this virus have 
analyzed only the E1-E2 and/or NS5A genes (Cuevas et al. 2009; Cuevas et al. 2008; 
Humphreys et al. 2009; Sheridan et al. 2004). This is due to the relevance of the 
proteins that they encode in the viral response to the immune system and to 
treatment and, in consequence, for the establishment of persistent infection. Similar 
studies using complete coding regions published so far (Campo et al. 2008; Cannon et 
al. 2008) have used methods for the inference of positive selection that lack power, as 
they are based on estimating the ratio of nonsynonymous to synonymous substitution 
rates (dN/dS) from the reconstruction of ancestral states (Nei and Gojobori 1986). 
Hence, we currently lack a detailed view of the action of selection as a factor in the 




Our goal in this work is to analyze the impact of positive selection on the 
evolution of the genomes of these two viral variants, comparing the selective 
pressures in the different proteins of these two subtypes. For this, we present analyses 
with a comprehensive dataset of complete HCV-1a and 1b genomes and report a 
detailed comparative map of positively selected sites using, for the first time in HCV, 
the mixed effects model of evolution (MEME) (Murrell et al. 2012). We have also 
estimated and compared the synonymous and non-synonymous substitution rates (dS 
and dN, respectively) and the heterozygosity (H) at individual sites. Finally, we have 
performed multivariate analyses in order to test the effects of RNA and protein 
structures and the presence of epitopes on the distribution of positively and conserved 
sites along their genomes. 
 The results obtained can give information to better understand the evolution of 
the HCV genome, especially genotype 1, regarding the effects of the different levels at 
which virus-host interactions can occur on genetic variability. The results can also 
indicate whether the most prevalent HCV-1 subtypes interact with the host in a similar 
way and have similar levels of genetic variability, or present differences which may be 
of interest to consider for antiviral research.  
 
Materials and Methods 
Full coding regions from HCV-1a and HCV-1b genomes were retrieved from the 
VIPRBRC dataset on May, 2013 (Pickett et al. 2012) (amino acid positions 1 to 3011, 
according to the reference genome H77- GenBank accession number AF011753). Only 
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sequences derived from human hosts were included. In addition, we ensured that all 
HCV sequences derived from DAA-naïve patients, excluding all sequences from DAA-
treated patients described in the literature up to January 2015. Additional inclusion 
criteria were: 
1- We included only one sequence per patient.  
2- Viral subtypes were confirmed using the COMET HIV-1/2 & HCV subtyping tool 
(Alcantara et al. 2009; De Oliveira et al. 2005, accessible at 
http://comet.retrovirology.lu). 
3- Recombinant sequences were detected and subsequently removed using five 
different methods implemented in the RDP3 software: RDP, Geneconv, 
Bootscan, Maxchi and Chimera (Martin et al.,2005; Martin and Rybicki 2000; 
Martin et al. 2010; Padidam et al. 1999; Posada and Crandall 2001). The 
criterion to remove putative recombinant sequences was to obtain significant 
results with at least two different methods. 
Multiple alignments were obtained for each HCV subtype independently using 
Muscle (Edgar 2004), as implemented in MEGA 5 (Tamura et al. 2011). 
The statistical power to detect sites under positive selection increases as the 
dataset contains more sequences (Kosakovsky Pond and Frost 2005). To deal with the 
differences in size between the final datasets of HCV-1a and HCV-1b (393 and 179 
sequences, respectively) we obtained 5 random subsets, each including half the total 
size of HCV-1a dataset (n=197), and performed the same positive selection analyses. 
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For each dataset, a phylogenetic tree was obtained with FastTree2 (Price et al. 
2009), using a GTR+GAMMA evolutionary model, as recommended by the AICM 
analyses implemented in jModeltest (Posada 2008). 
 Considering diversifying selection as adaptive evolution in which increasing the global 
variability is favored in the population (Murrell et al. 2012), for each dataset and its 
corresponding tree, two different diversifying positive selection analyses were 
performed: (1) the two-rate Fixed Effects likelihood (FEL), a maximum-likelihood (ML) 
method used to find independent sites under positive, neutral or purifying selection 
which considers that both dN and dS can vary between sites, while dN/dS remains 
constant along the different lineages of a given phylogenetic tree (Kosakovsky Pond 
and Frost 2005); and (2) Mixed Effects Model of Evolution (MEME), an extended 
version of FEL which considers that dN/dS can change across lineages. This method has 
been reported to be more efficient in finding sites under positive selection than FEL. 
Furthermore, it has been recommended for finding both episodic (that affects only to a 
subset of lineages) and pervasive (that affects to a large proportion of positively 
selected sites) selection, with a type I error probability not higher than 0.05 (Murrell et 
al. 2012). Both analyses were performed with Hyphy (Kosakovsky Pond and Muse 
2005) using the GTR model of nucleotide substitution and setting the significance level 
at 5%. Given that MEME and FEL are nested models, we compared their performance 
by calculating the ratio of their log-likelihoods (LRT) at each positively selected codon 
(Murrell et al. 2012). According to a Chi-square distribution with 2 degrees of freedom, 
LRT values larger than 5.99 were considered to be significant (P-value < 0.05).  
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A parsimony analysis was performed with MacClade 4.08 (Maddison and Maddison 
2005) in order to infer the number of changes accumulating in each branch of the HCV-
1a and HCV-1b phylogenies, considering only the detected positively selected codons. 
This analysis allowed us also to detect sites identified as being under positive selection, 
but whose genetic variability was only due to singletons. Such sites were not 
considered for further analyses. This decision was taken in order to minimize the 
presence of false positives that could actually be sites in which a deleterious mutation 
had occurred but had not been removed from the viral population at the time of 
sampling. The remaining positively selected sites were mapped according to the H77 
reference genome. 
The number of sites under purifying selection was calculated from the list of 
negatively selected sites found in FEL. Then, we discarded those sites that actually 
were under positive selection, as detected by MEME.  
For each subtype, a list of neutrally evolving sites was also obtained by means of 
the following procedure: 
1- For each HCV subtype, a list of sites not evolving under positive nor negative 
selection was obtained from the results of FEL, as neutral evolution is 
considered the null hypothesis. 
2-  Potentially neutral sites that were actually positively selected, as detected by 
MEME, were excluded.  
3- Completely conserved sites were also excluded, as they were considered to be 
under very strong purifying selection: it is possible that no variation is found in 
these positions, because mutations that have occur are deleterious, and are 
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quickly removed from the viral populations. For this reason, we decided not to 
consider these sites as neutral. Importantly, when a site has no variation, then 
the LRT from FEL or MEME may not have enough statistical power to reject the 
null hypothesis of neutrality of these methods (Nei 2005).  
Gene diversity (H) at each amino acid and nucleotide site (first, second and third 
codon positions) was calculated using the expression H=1-∑pi
2 (where pi is the 
frequency of each allele at a given site) (Beebee and Rowe 2008). dN, dS and H values 
were compared between subtypes using independent Mann-Whitney tests for: a) all 
genomic codons; b) positively selected codons and c) neutrally evolving codons. P-
values obtained from non-independent statistical tests were corrected by means of 
False Discovery Rate corrections (FDR; (Benjamini and Hochberg 1995). 
Frequencies of base-pairing at each nucleotide position for each HCV subtype were 
estimated with the software STRUCTURE_DIST (Tuplin et al. 2004), which analyses 
multiple RNA-folding patterns predicted by MFOLD (Zuker 2003). Antibody, CD8 and 
CD4 T-cell epitope positions were retrieved from the Los Alamos National Laboratory 
website (http://hcv.lanl.gov/content/immuno/immuno-main.html) and the Immune 
Epitope Database and Analysis resource (http://www.iedb.org) on June, 2015. Only 
human epitopes from HCV genotype 1 were included. Protein structures in both 
subtypes were inferred with JPred4 (Drozdetskiy et al. 2015), which predicts the 
location of secondary structures of proteins (alpha helixes, beta sheets) from multiple 




Logistic regression analyses (general linear model, GLM) were performed to 
compare, in each subtype, the distribution of positively selected and conserved 
positions. Several binary variables at each position were considered in the linear 
models: (1) RNA base-pairing (consensus, ≥ 0.50) at the subtype level (given that RNA 
structure applies to individual nucleotide positions, but selection acts at the codon 
level, we considered a codon as “structured” if at least 2 of the 3 positions were 
paired), (2) CD8 T-cell epitope, (3) CD4 T-cell epitope, (4) antibody epitope, (5) alpha 
helix, and (6) beta sheet. Positions were considered to be conserved if they had H = 0 
at the amino acid level. An initial model, which included all the variables, was built. 
Stepwise model selection by Akaike Information Criterion (AIC) was performed with 
the R package “MASS” (Ripley et al. 2012) with the aim of including only relevant 
predictors. Stepwise search was performed in both directions (which tests at each step 
for variables to be included or excluded), and the best quality model for the GLM was 
chosen as the one with the lowest AIC value. P-values obtained in the logistic 
regression analyses were corrected by means of FDR. All statistical tests were 
performed as implemented in R (R Core Team 2015).  
Results 
In total, 415 sequences from HCV-1a and 204 sequences from HCV-1b were 
retrieved. All sequences were correctly subtyped (no evidence of inter-subtype 
recombination was found) and, after removing duplicated and/or intra-subtype 
recombinants, the final data sets consisted of 393 HCV-1a and 179 HCV-1b sequences.  
FEL analyses detected 95 and 62 positively selected sites along the HCV-1a and 
HCV-1b genomes, respectively. In contrast, MEME analyses detected 315 (total dataset 
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of HCV-1a) and 248 (HCV-1b) sites under positive selection. From those, 282 sites 
(HCV-1a) and 211 (HCV-1b) were not singletons (found only in one external branch) 
and were retained for ensuing analyses. All positively selected sites found by FEL were 
also found by MEME, and all these sites represented 9.4% and 7.0% of the total length 
of 1a and 1b protein encoding genomes, respectively. Ninety-nine homologous sites 
were found to be positively selected in both subtypes. Additional details of these 
analyses are provided in Supplementary Table S1A and S1B (Supplementary Material 
online), including information on the genome location of each selected position, the 
frequency at which each selected site found in the full set of HCV-1a was also detected 
in the five subsets and LRT comparisons between MEME and FEL.  
The performance of MEME and FEL for the detection of positively selected sites 
was compared by performing LRTs at each positively selected position detected by 
MEME. The mixed effects model outperformed the fixed effects model in most 
positions (209 of 282 in HCV-1a and 159 of 211 in HCV-1b), and could never be 
considered as significantly worse than FEL for the inference of positive selection in the 
datasets analyzed (Supplementary Tables S1A and S1B, Supplementary Material 
online). 
Table 1 summarizes the distribution of positively selected sites along the 
different regions of the H77 reference polyprotein for the two HCV-1 subtypes and for 
the 5 random subsets of HCV-1a.  
After considering those sites initially found to be under purifying selection by 
FEL (n=2412 in HCV-1a; n=2672 in HCV-1b), but that were actually under positive 
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selection (as detected by MEME), there were 2256 and 2571 sites significantly 
associated with purifying selection in HCV-1a and 1b, respectively. 
A list of neutral sites was obtained from those sites that were not found to be 
under positive or negative selection in FEL or MEME and that were not totally 
conserved. We found that 231 in HCV-1a (7.7% of the total genome) and 271 positions 
in HCV-1b (9.0%) were evolving under neutrality (dN=dS). Of them, only 74 
homologous positions were coincident in both subtypes (Supplementary Table S1C, 
Supplementary Material online).  
 Supplementary Figs. S1A and S1B (Supplementary Material online) show the 
phylogenetic trees obtained from the HCV-1a and HCV-1b complete genome 
sequences, respectively. In these trees, the branches are colored according to the 
number of positively selected sites changing along each branch, as determined by 
parsimony using MacClade 4.08 (Maddison and Maddison 2005). Changes at positively 
selected sites were observed in both internal and external branches, although most 
changes accumulated in external branches. 
 Differences in the number of positively selected sites between proteins were 
found. The protein with the highest proportion of sites under positive selection was E2, 
followed by NS2 and E1. The proteins with the lowest proportion of sites under 
positive selection were NS4A and Core (Table 1). HCV-1b tended to present more 
positively selected sites in the second hypervariable region (HVR2) of E2 (mean = 1.4 
sites in the subsets of HCV-1a, vs 6 sites in HCV-1b), in P7 (1.8 sites in HCV-1a vs 5 sites 
in HCV-1b) and the NS3-helicase (13.8 sites in HCV-1a vs 21 in HCV-1b). HCV-1a 
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presented more positively selected sites only in Core (5.8 sites in HCV-1a, vs 3 in HCV-
1b) (Table 1).  
 Mean and standard error (SE) estimates of dS, dN and heterozygosity (for both 
amino acids and nucleotides) obtained for the whole genomes, positively selected sites 
and neutral sites are available in Supplementary Tables S2A-C (Supplementary Material 
online), respectively, and in Figure 1. After applying the FDR corrections, the 
heterozygosity at third codon positions was found to be significantly higher in HCV-1b 
than in HCV-1a at the genomic level (HCV-1a: 0.161 ± 0.002 – mean ± standard error, 
HCV-1b = 0.181 ± 0.003; P <0.001). No significant differences were found in first or 
second codon positions nor amino acid sites (all P values > 0.05) (Fig1.A; 
Supplementary Table S.2 A). 
Mann-Whitney tests comparing heterozygosity between subtypes in all codon 
positions and amino acids and dS and dN of all positively selected sites revealed that 
HCV-1b presents significantly higher dN (HCV-1a: 1.257 ± 0.192 , HCV-1b: 1.563 ± 
0.271; P = 0.040) and heterozygosity at amino acids (HCV-1a: 0.239 ± 0.013, HCV-1b: 
0.308 ± 0.016; P <0.001), first codon positions (HCV-1a: 0.155 ± 0.011, HCV-1b: 0.214 ± 
0.013; <0.001), second codon positions (HCV-1a: 0.123 ± 0.010, HCV-1b: 0.169 ± 0.013; 
P = 0.003) and third codon positions (HCV-1a: 0.183 ± 0.010; HCV-1b: 0.206 ± 0.011; P 
= 0.023), but not significantly different dS (P = 0.90) (Fig1.B; Supplementary Table S.2 
B).  
For neutral sites, no significant differences in dS, dN nor in heterozygosity 
between HCV-1a and HCV-1b were found, as concluded from the statistical tests (all P 
values > 0.05) (Fig1.C; Supplementary Table S.2 C). 
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A map of the HCV-1a and HCV-1b genomes representing the different layers of 
data analyzed (conservation, positive selection, RNA structure, protein structure and 
epitopes for antibodies, CD8 and CD4 T cells) is shown in Fig. 2. In the logistic 
regression analyses, the models with the lowest AIC values were “RNA structure + CD4 
epitope + CD8 epitope + Alpha helix” for HCV-1a and “RNA structure + CD4 epitope + 
CD8 epitope + Beta sheet” for HCV-1b. Comparing the distribution of positively and 
conserved sites at such layers of data revealed, for both HCV-1a and 1b, a positive 
association between conservation and secondary structure as well as with CD4 T cell 
epitopes. In contrast, although a positive association between selection and CD8 T cell 
epitopes was found in this case the P-values for both subtypes were > 0.05 after the 
FDR correction (Supplementary Tables S3A and S3B, Supplementary Material online). 
The same analyses were performed for all genes in which at least 10 sites were 
found to be positively selected in both subtypes (E1, E2, NS2, NS3, NS5a and NS5b). In 
HCV-1a, a positive association between selection and the presence of CD8 epitopes 
was found in NS2, although the P-value increased to > 0.05 after FDR correction. In 
subtype 1b, a similar association between conservation and the presence of CD4 
epitopes was found in NS3. Although associations between selection and CD8 epitopes 
and between conservation and the presence of beta sheets were found in E2 of HCV-
1b, the P-value increased to > 0.05 after FDR correction (Supplementary table S.3A and 
S.3B). 
Discussion 
In this work we have performed a comparative analysis of the evolutionary 
forces that shape the genomes of HCV-1a and HCV-1b, using both a fixed effects (FEL) 
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and a mixed effects model (MEME) to detect sites evolving under different selective 
pressures: positive, purifying or neutral. Our results reveal several differences as well 
as similarities between these two relevant subtypes of HCV and help us understand 
the underlying factors driving their evolution at the genome level. 
Previous studies analyzing selection in the HCV genome are more conservative 
than this one because they are based on the Nei and Gojobori model (1986) for the 
calculation of dN/dS. Campo et al. (2008) found a very similar number (n= 60) of sites 
evolving under positive selection along the HCV-1b genome using the SLAC method to 
those we found with FEL (n=62). However, our analysis with MEME detected more 
than 3 times more positively selected sites than these studies, in line with the 
expected increased power of this method (Murrell et al. 2012). In consequence, 
methods for the detection of positively selected sites that do not take into account 
that dN/dS can vary among lineages may underestimate the number of positively 
selected sites. This can occur when, for a given site, purifying selection prevails in most 
lineages, masking the detection of episodic positive selection occurring in a restricted 
number of lineages.  
Amino acid changes in positively selected codons accumulated mainly on the 
external branches of the phylogenetic trees for both viral subtypes. This was expected, 
because the methods used to detect positive selection in fact identify sites under 
adaptive diversification when applied to the population or within-species level. 
Diversifying selection is known to be of major importance in the adaptive evolution of 
HCV, in which increasing global variability would be favored (Cuevas et al. 2009). 
Another possible explanation is that recent deleterious mutations, most of which are 
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expected to be nonsynonymous, may not have been purged by selection yet and they 
will likely map on the external branches of the phylogeny. In consequence, for a given 
position different nonsynonymous substitutions might be detected as being positively 
selected when analyzing viral sequences from different patients when they actually 
represent transient polymorphisms at the population level. However, we excluded 
singletons from the list of positively selected positions and analyzed only one sequence 
per patient, thus minimizing the presence of these false positives.  
We also found that purifying selection plays a major role in the evolution of 
HCV, with more than 2200 codons estimated to be under purifying selection in both 
subtypes. However, the number of neutral sites inferred from our work differs 
markedly from those detected by Campo et al. (2008) (833 sites). This discrepancy 
might be explained by the different sampling sizes used in both studies (114 vs 179 
HCV-1b sequences) but it is more likely due to differences in the methodology used in 
the two studies. The lower power of SLAC (Kosakovsky Pond and Frost 2005) used by 
Campo et al. (2008) to reject the null hypothesis of neutrality would be reflected in a 
large number of undetected, negatively selected sites. Furthermore, our criteria to 
detect neutral sites were more stringent, including only sites that were considered not 
to be positively nor negatively selected in MEME and FEL and which presented H > 0 at 
the amino acid level, to avoid including codons under very strong, purifying selection 
for which no change could be detected.  
We found positively selected sites in all HCV genes. Differences between 
subtypes in the distribution of positively selected sites were also detected. Whereas 
HCV-1b tended to present more positively selected sites in E2 (HVR2), P7 and NS3 
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(helicase), HCV-1a presented more positively selected sites in the Core gene. This 
observation is based on the results obtained from the random subsets of HCV-1a, with 
a similar number of sequences to that obtained for HCV-1b. These subsets presented 
very similar levels of heterozygosity, dS, and dN when compared to the whole dataset 
of this subtype. Hence, differences between the two subtypes in these parameters are 
not likely due to their different sample sizes. 
Differences in H between both subtypes were significant at the amino acid level 
and at first, second and third codon positions of positively selected sites and only at 
third codon positions at the complete genome level. In contrast, differences in dN 
between the two subtypes were significant only for positively selected sites, whereas 
no significant differences in dS were detected in any of the comparisons performed. 
The different phylodynamic histories of HCV-1a and HCV-1b (Magiorkinis et al. 2009) 
could explain the higher genetic variability in third codon positions of HCV-1b at the 
genomic scale. HCV-1b started its explosive growth 20 years earlier than HCV-1a and 
its current effective infection size remains higher. This implies that it may have 
accumulated more genetic variability. Although no significant differences were found 
at first and second codon positions, where most changes are non-synonymous (a 
majority of these sites are totally conserved along the HCV genome), the significantly 
higher variability of HCV-1b with respect to HCV-1a was evident at third codon 
positions, in which most changes are synonymous. Interestingly, we did not find 
significantly higher dS values in HCV-1b. According to the neutral theory of evolution, 
dS depends only on the neutral mutation rate but H is dependent also on the effective 
population size (Kimura 1983). In consequence, we would expect HCV-1a and HCV-1b 
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to present similar dS if their overall mutation rates are similar but to differ in H if they 
have different effective population sizes. 
Despite the differences found in the distribution of positively selected sites, 
multivariate analyses at the genomic level revealed that HCV-1a and HCV-1b evolve 
under similar forces and constraints (RNA structure and CD4 T cell epitopes favoring 
conservation, and CD8 T cell epitopes favoring selection). Snoeck et al. (2011) mapped 
positively selected sites along the genome of HIV-1 and found that structured RNA and 
alpha helices in protein structure were associated with conservation whereas CD4 T-
cell and antibody epitopes were associated with positive selection. However, they also 
found a significant association between CD8 and CD4 epitopes and conservation for 
several genes. Our results, regarding the overall association between secondary 
structure and conservation, are in line with those of Snoeck et al. (2011) and also with 
the results obtained by Mauger et al. (2015) with HCV. These authors suggested that 
conservation of secondary structures in this virus could facilitate persistent infection 
by masking the viral genome from degradation by RNase L and innate antiviral 
defenses (Li and Lemon 2013; Washenberger et al. 2007).  
In contrast to Snoeck et al. (2011) with HIV-1, we found no relevant association 
between antibody epitopes or protein structure and conservation or selection in HCV. 
Although the role of CD4 and CD8 T-cells in the immune response to HCV is well 
known, contrary to other viruses such as HIV or HBV (Koziel 2005) there is not a clear 
pattern of antibodies response that distinguishes between recovery and chronic 
infection in HCV. Thus, further research to clarify their role in controlling HCV 
19 
 
replication and to which extent such mechanisms influence on the evolution of HCV is 
certainly needed.  
Recently, Geller et al. (2016) estimated the per site mutation rate along the 
HCV genome, and found a small reduction in sites predicted to form base pairs. We 
performed a univariate analysis to check whether there was an unequal distribution 
between sites with low and high mutation rates, considering conserved and selected 
codons, and found no significant differences (Fisher’s exact test P > 0.20 in both 
subtypes). 
The association between CD4 T-cell epitopes and conservation is remarkable. 
Given that epitopes are targets for the host immune system, it would be reasonable to 
expect epitopes to be under positive or diversifying selection (as for CD8), because an 
increased genetic variability would facilitate viral escape from the immune system. 
However, several studies have observed very conserved epitopes in HCV and other 
viruses (Lamonaca et al. 1999; Sanjuán et al. 2013; Sarobe et al. 2001; Snoeck et al. 
2011). Sanjuán et al. (2013) suggested that HIV may take advantage of immune 
activation, thus favoring epitope conservation. Hence, if HCV also benefits from 
immune activation, the design of vaccines based on conserved epitopes would be 
detrimental.  
After this manuscript was written, Cuypers et al. (2016) have published their 
analysis of the different distributions of positively selected and conserved sites in HCV 
considering variables such as protein and RNA secondary structure and B-cell, CD8 and 
CD4 epitopes. We were unaware of this paper during the development of our work. 
Despite using larger datasets, they found a similar proportion of sites under purifying 
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selection (approximately 2500 positions) and less than 100 positively selected sites in 
each HCV subtype, probably because the positive selection analyses were performed 
using FEL, and not MEME. Indeed, these numbers are very similar to the positively 
selected sites that we found in HCV-1a with FEL, and is in agreement with previous 
observations which evidenced that methods for the detection of positive selection can 
be conservative for smaller sample sizes, but not for larger (Kosakovsky Pond and 
Frost, 2005; Murrell et al, 2012). In addition, the distribution of positively selected sites 
was similar in both works.  
As expected, Cuypers et al. (2016) obtained similar results to ours for the 
association between conservation and RNA structure and CD4 epitopes. Such 
similarities were expected because, in both studies, the mapping of RNA secondary 
structure was performed computationally and the mapping of epitopes was a based on 
information available at public databases. However, some discrepancies were also 
obtained: they found an association between positive selection and CD8 epitopes only 
in HCV-1a, while we did not find inter-subtype differences. In addition, they obtained 
significant associations between different protein structures (alpha helix and B-sheets) 
and conservation, whilst we did not find any significant association for these two 
variables. Although Cuypers et al. (2016) used protein structure information derived 
from crystallized or nuclear magnetic resonance (NMS) when available, the extensive 
lack of such information for the HCV proteome led both studies to predict such 
structures by means of computational methods. Consequently, differences in the 
methodology used for mapping protein structures, including the use of different 
protein structure prediction programs, may have caused these incongruent results. 
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 Is also important to point out that, unlike Cuypers et al. (2016) our work 
included a comparison of FEL and MEME, allowing to observe that most positively 
selected sites are under episodic/pervasive selection, hampering their detection when 
using more conservative, less powerful methods, such as FEL. Finally, our comparisons 
of the genetic variability (heterozygosity), and dN and dS, of HCV-1a and 1b along their 
genomes, as discussed above, have not been performed, or published, before. 
In conclusion, we have produced a detailed map of positive selection along 
HCV-1a and 1b genomes and analyzed which variables can impose constraints or be 
associated to selection. We have shown that, despite purifying selection being the 
most extensive evolutionary process acting on HCV, positive selection affects all genes 
along the HCV genome. Although there are differences in variability and the 
distribution of positively selected sites, both viral subtypes share similar selective 
pressures along their genomes. The results obtained from this study give information 
about the effect of some of the interactions between HCV and its host on HCV 
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Figure 1. Barplots, with standard errors error bars, representing the mean 
heterozygosity, dS and dN values of the total genome (1.A), positively selected sites 
(1.B) and neutral sites (1.C) for both HCV-1a (blue) and HCV_1b (red).  
Figure 2. Map of the HCV-1a and 1b genomes, indicating the location of totally 
conserved amino acids (black), positively selected sites (blue) RNA secondary 
structures present in at least 50% of the sequences of each dataset (purple), CD8 T cell 
epitopes (red), CD4 T cell epitopes (orange), antibody (AB) epitopes (brown), alpha 
helixes (pink), beta sheets (green). 
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Supplementary Fig. S1. Trees obtained with FastTree2 (model GTR + GAMMA). Branch 
color represent the number of changes occurring at each branch, and branch lengths 
the number of changes accumulated along the phylogeny, considering only positively 
selected sites. Fig. S1A: HCV-1a. Fig. S1B: HCV-1b. 
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Table 1. Number positively selected sites, and its proportion (between brackets) at each gene of HCV-1a and HCV-1b. aa-number of amino acids encoded by each gene. n – number of 
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